JPRN-UMIN000015369已完成未知
The study of dapagliflozin (sodium glucose cotransporter 2 inhibitor) to verify the efficacy of combination therapy in Japanese patients with type 2 diabetes - DISCOVERY study
Okayama University Hospital nephrology, diabates and endocrinology0 个研究点目标入组 100 人开始时间: 2014年10月8日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) type 1 diabetes 2) BMI: >= 45 3) patients suspected of pregnancy or pregnant or nursing 4) diabetes insipidus 5) severe liver dysfunction (liver cirrhosis, viral hepatitis, AST: >= 3 times of upper limit) 6) moderate renal dysfunction (eGFR: < 45 ml/min/1.73m2) 7) heart disease (myocardial infarction, unstable angina) or stroke within 3 months 8) considered as inadequate by the investigator
研究者
相似试验
已完成
不适用
sage of Dapagliflozin in the management of Type-2 Diabetes Mellitus in Indian patientsCTRI/2017/03/008011AstraZeneca Pharma India Ltd
已完成
4 期
Effect of Dapagliflozin on Vascular Functions in Patients With Type 2 Diabetes Compared to GliclazideDiabetesNCT02610088Seoul National University Bundang Hospital32
已完成
不适用
Usage of Dapagliflozin in the Management of Type-2 Diabetes Mellitus: A Real World Evidence Study in Indian PatientsType 2 DiabetesNCT03071016AstraZeneca2,000
进行中（未招募）
1 期
Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney DiseaseChronic Kidney DiseasesKidney DiseasesHeart FailureHeart FailureNCT05719714Northwestern University18
已完成
不适用
The potential effect of Dapagliflozin on diabetic macular edemadiabetic macular edema, diabetesJPRN-UMIN000020331Kyoto Prefectural University of Medicine Department of Endocrinology and Metabolism45